Ann: Increased Scheme Consideration from Pfizer, page-310

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 310 Last

Share
Profile

Follow
pilko3

6,864 Posts.

885

20/06/22

11:32

Post #: 62089548
Share
Originally posted by TerribleTadpole: ↑

Do you mean the independent expert has baked it in? I don't think that's possible because:
There's no mention of a data validation dependency in the tiny amount of information passed on in the public announcements.
The independent expert can't possibly have known about the data validation test because that was agreed between Pfizer and ResApp after the independent expert supplied the draft report.

I believe the "fair and reasonable" price range offered by the independent expert reflect s the considerable unknowns with a pre-revenue micro-cap med-tech company with no commercial history for its established product, and regulatory/financial risks for its new product.

I suspect the conversation between ResApp and Pfizer after the draft report was received went something like this:
ResApp: IER says not in shareholders' best interests. It has to be between 14.6c and 27.7c to get the independent expert's nod.
Pfizer: Okay, we'll offer 14.6c.
ResApp: Be serious! You think that's going to make the grade when the shareholders see a top end of 27.7c? Go mid-point at least.
Pfizer: How do we know we're not buying a pup? What if this thing doesn't make the grade and we have to tip in half a billion more just to make it work?
ResApp: How about if we can prove it's good as it is? Would you go mid-point then?
Pfizer: Okay, deal. But if it flops we're not going over 14.6c. And by the way we're not satisfied that you're doing enough to promote this takeover. It looks to us like you're doing the minimum you think you can get away with. If we go in with a conditional mid-point offer you're going to have to step up and really start promoting this thing seriously. Don't think we'll hold back if we think you've broken your part of the bargain!

Expand

You suffering from Mondayitis TT? No offence meant of course...
RAP Price at posting: 17.5¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 68 more messages in this thread...

First 310 Last

Add RAP (ASX) to my watchlist

Ann: Increased Scheme Consideration from Pfizer, page-310

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News